251 Efficacy and safety of iparomlimab and tuvonralimab in previously treated patients with recurrent or metastatic cervical cancer: a multicenter, open-label, single-arm, phase 2 clinical trial (DUBHE-C-206)
Hanmei Lou(Zhejiang Cancer Hospital), Jihong Liu(Sun Yat-sen University), Xiaoyan Kang(Qilu Hospital of Shandong University), Wei Duan(Deakin University), Lihua Wang(Jiangxi University of Traditional Chinese Medicine), Chao Wang(Qilu Hospital of Shandong University), Dapeng Li(Huazhong Agricultural University), Hui Li(Shandong Tumor Hospital), Mingjun Zhang(Anhui Medical University), Hongping Zhang(Kunming Medical University), Yun Zhou(Fujian Medical University), Huijun Cheng(Henan Cancer Hospital), Shilin Xue(Qilu Hospital of Shandong University), Zi Liu(First Affiliated Hospital of Xi'an Jiaotong University), Mei Feng(Union Hospital)
Cited by 5
Related Papers
Lnc2Cancer: a manually curated database of experimentally supported lncRNAs associated with various human cancers
|Nucleic Acids Research|2015|386
Gold nanoparticles and gold nanorods in the landscape of cancer therapy
|Molecular Cancer|2023|310
The mRNA related ceRNA–ceRNA landscape and significance across 20 major cancer types
|Nucleic Acids Research|2015|209
Modulating influence on HIV/AIDS by interacting <i>RANTES</i> gene variants
|Proceedings of the National Academy of Sciences|2002|189